Enteric encephalopathy, 1456

Enteric gram-negative bacilli, 996

Enterobacter meningitis, 1378

Enterobacter species, 977

Enterobiasis, 1708

E. vermicularis ectopic lesions, 1708

prevalence of, 1708

signs of, 1708

symptoms of, 1708

treatment, 1708

Enterochromaffin-like (ECL) cells, 482

Enterococcal endocarditis, 1396–1399

Enterococcal infection, 1479

Enterococcus, 977

Enterocutaneous (EC) fistulas, 804

Enterotoxigenic E. coli (ETEC), 1461

Environmental Protection Agency (EPA), 847

Enzyme-linked immunosorbent assays (ELISA), 1582

Enzyme supplementation, 457–458

Eosinophilia, 636

Eosinophils, 34

and asthma, 378

EPA (see Eicosapentaenoic acid (EPA); Environmental Protection Agency (EPA))

Epidemiology of Diabetes Interventions and Complications (EDIC), 1078

Epidermal necrolysis, 822

Epidermis, 807–808, 808f

Epididymitis, gonococcal infection and, 1507

Epigastric pain syndrome, 487

Epilepsy

classification of, 1274t

definition of, 1274

and EPT, 2276

syndromes, 1275, 1275t

treatment of, 1280–1296

and women related issues, 1296–1298

Epsilometer test (E test), 1331, 1395

ERCP (see Endoscopic retrograde cholangiopancreatography (ERCP))

Erectile dysfunction (ED), 2098, 2258–2259, 2259–2266

in cigarette smokers, 2263

diabetes mellitus associated with, 2263

diagnosis of, 2260–2262

drug-induced, 2261–2262t, 2263–2264

due to neurogenic disorders, 2259

and endocrine disorders, 2263

and gonadal function, 2263

hormonal cause of, 2259–2260

hypertension and, 2262–2263

management of, 2264

pathogenesis of, 2259

pharmacotherapy for, 2264–2266

signs of, 2260

symptoms of, 2260

and testicular size, 2263

and testosterone production, 2263

vascular disease associated with, 2260

ERICA (see Efficacy of Ranolazine in Chronic Angina (ERICA))

Erysipelas, 1549

Erythema migrans, 1719

Erythema multiforme (EM), 822

Erythema nodosum, 454

eruptions, 822–823

Erythrocyte deformability, 164

Erythrocytes (see Red blood cells (RBCs))

Erythrocyte sedimentation rate (ESR), 33, 520

Erythrodermic psoriasis, 833 (see also Psoriasis)

Erythropoiesis-stimulating agent (ESA), 612

Erythropoietic therapy, 1942–1943

ESA (see Erythropoiesis-stimulating agent (ESA))

Escherichia coli, 977–978, 1323, 1327t, 1329t, 1346, 1472, 2161

and infectious diarrhea, 1462–1463

ESMID (see European Society for Microbiology and Infectious Diseases (ESMID))

Esophageal acid clearance, 503

Esophageal candidiasis, 1597

Esophageal manometry, 507

Esophageal varices

treatment, 546–551, 548t

alternative treatment modalities, 549

balloon tamponade, 549

endoscopic variceal ligation and sclerotherapy, 548–549

general management, 547

goals of therapy, 546

hypovolemia/blood loss, 547

infection prophylaxis, 549

octreotide, 547

primary prophylaxis, 549–550

secondary prophylaxis, 550–551

terlipressin, 547–548

vasopressin, 547

Esophagogastroduodenoscopy (EGD), 493

ESR (see Erythrocyte sedimentation rate (ESR))

ESRD (see End-stage renal disease (ESRD))

ESSENCE (see Efficacy and Safety of Subcutaneous Enoxaparin (ESSENCE))

Essential fatty acid deficiency (EFAD), 795

Essential hypertension, 132–160

Essential nutrients (water), 748

Essential tremor (ET)

clinical presentation of, 1270–1271

diagnosis of, 1271

and Parkinson’s Disease, 1270t

treatment of, 1271–1272

Estimated glomerular filtration rate (eGFR), 24, 114, 1012

blood chemistry reference values for, 17t

ET (see Essential tremor (ET))

ETEC (see Enterotoxigenic E. coli (ETEC))

E test (see Epsilometer test (E test))

EULAR (see European League Against Rheumatism (EULAR))

European Association for Study of Liver (EASL), 540, 551, 552, 554

European League Against Rheumatism (EULAR), 706, 869

European Respiratory Society, 510

European Society for Microbiology and Infectious Diseases (ESMID), 1486

E

u

t

e

c

t

i

c

m

i

x

t

u

r

e

o

f

l

o

c

a

l

a

n

e

s

t

h

e

t

i

c

s

(

E

M

L

A

)

,

2

1

3

0

E

u

t

h

y

r

o

i

d

i

s

m

,

1

0

5

6

E

u

t

h

y

r

o

i

d

p

a

t

i

e

n

t

s

,

1

0

4

5

,

1

0

4

6

,

1

0

5

7

thyr

o

id

fun

c

t

io

n

t

e

s

t

s

in

,

1

0

4

0

t

E

u

t

h

y

r

o

i

d

s

i

c

k

s

y

n

d

r

o

m

e

,

1

0

4

6

E

v

a

l

u

a

t

i

o

n

o

f

L

o

s

a

rt

a

n

i

n

t

h

e

E

l

d

e

rl

y

(

E

L

I

T

E

)

,

2

8

2

E

VE

R

E

S

T

t

ri

a

l

,

2

6

7

E

VL

(

s

e

e

E

n

d

o

s

c

o

p

i

c

v

a

ri

c

e

a

l

l

i

g

a

t

i

o

n

(

E

VL

)

)

E

x

c

e

s

s

i

v

e

d

ayt

i

m

e

s

l

e

e

p

i

n

e

s

s

(

E

D

S

)

,

1

7

6

4

E

x

c

r

e

t

i

o

n

/

e

l

i

m

i

n

a

t

i

o

n

o

f

d

r

u

g

s

,

4

3

E

x

e

r

c

i

s

e

dia

b

e

t

e

s

a

n

d

,

1

0

8

0

a

n

d

GD

M

,

9

8

1

I

C

a

n

d

,

1

6

9

a

n

d

o

s

t

e

op

o

r

o

s

is

,

2

2

7

2

,

2

2

8

2

P

A

D

a

n

d

,

1

6

6

fo

r

P

C

O

S

,

1

0

1

1

a

n

d

p

r

e

me

n

op

a

u

s

a

l

w

o

me

n

,

2

2

7

3

fo

r

s

t

imula

t

in

g

o

s

t

e

o

b

la

s

t

ic

a

c

t

iv

ity

,

2

2

8

1

s

tr

e

s

s

t

e

s

t

in

g

,

2

2

0

p. 2

3

3

8

p. 2

3

3

9

E

x

e

r

c

i

s

e

-

i

n

d

u

c

e

d

a

s

t

h

m

a

(

E

I

A

)

,

4

0

0

–

4

0

1

E

x

e

r

c

i

s

e

t

o

l

e

r

a

n

c

e

t

e

s

t

,

2

1

2

,

2

2

0

E

x

e

rt

i

o

n

a

l

a

n

g

i

n

a

,

2

0

8

E

x

p

a

n

d

e

d

D

i

s

a

b

i

l

i

t

y

S

t

a

t

u

s

S

c

a

l

e

(

E

D

S

S

)

,

1

2

1

9

E

x

p

e

rt

P

a

n

e

l

R

e

p

o

rt

3

(

E

P

R

-

3

)

,

3

7

8

E

x

t

e

r

n

a

l

d

e

fi

b

ri

l

l

a

t

i

o

n

,

3

2

9

–

3

3

0

E

x

t

r

a

c

e

l

l

u

l

a

r

fl

u

i

d

(

E

C

F

)

,

2

1

E

x

t

r

a

e

s

o

p

h

a

g

e

a

l

m

a

n

i

fe

s

t

a

t

i

o

n

s

,

5

0

9

–

5

1

1

GE

R

D

a

s

thma

a

n

d

,

5

1

0

o

t

o

la

r

yn

g

o

lo

gy

s

ymp

t

o

m

s

a

n

d

,

5

1

0

tr

e

a

tme

nt

o

f,

5

1

1

n

o

n

c

a

r

dia

c

c

h

e

s

t

p

a

in

,

5

1

0

E

x

t

ri

n

s

i

c

a

s

t

h

m

a

,

3

7

8

E

y

e

l

a

s

h

e

s

,

1

1

4

9

E

y

e

l

i

d

s

,

1

1

4

9

E

y

e

s

a

n

a

t

o

my

o

f,

1

1

4

9

,

1

1

4

9

f

b

lin

dn

e

s

s

,

dia

b

e

t

e

s

a

n

d

,

1

1

4

9

–

1

1

5

0

c

h

e

mic

a

l

b

ur

n

s

in

,

1

1

6

4

dis

o

r

d

e

r

s

w

ith

,

1

1

6

4–

1

1

6

5

e

me

r

g

e

n

c

ie

s

w

ith

,

1

1

6

4

p

hy

s

io

lo

gy

o

f,

1

1

4

9

,

1

1

4

9

f

FF

a

c

e

s

p

a

i

n

s

c

a

l

e

(

F

P

S

)

,

1

1

7

5

t

F

a

c

t

o

r

V

L

e

i

d

e

n

,

9

3

4

F

A

E

R

S

(

s

e

e

F

D

A

A

d

v

e

r

s

e

E

v

e

n

t

R

e

p

o

rt

i

n

g

S

y

s

t

e

m

(

F

A

E

R

S

)

)

F

a

l

l

s

,

P

a

r

k

i

n

s

o

n

’

s

d

i

s

e

a

s

e

a

n

d

,

1

2

6

7

–

1

2

6

8

F

a

m

i

l

i

a

l

c

o

m

b

i

n

e

d

h

yp

e

rl

i

p

i

d

e

m

i

a

(

F

C

H

L

)

,

1

0

6

t

,

1

0

7